Join
Live feed
·
PRReleasevia Quantisnow
COMPASS Pathways Plc logo

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

ByQuantisnow·Wall Street's wire, on your screen.
CMPS· COMPASS Pathways Plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CMPS (COMPASS Pathways Plc) and more on Quantisnow.